-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
NEXGEL Appoints Dr. Leonard Nelson and Dr. Neil Chesen to Scientific Advisory Board
NEXGEL Appoints Dr. Leonard Nelson and Dr. Neil Chesen to Scientific Advisory Board
LANGHORNE, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that the Company has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board.
Dr. Nelson serves as Co-Director of the pediatric ophthalmology department and Director of the Strabismus Center at Wills Eye Hospital. He is an associate professor of ophthalmology and pediatrics at Thomas Jefferson University's Sidney Kimmel Medical College and staff member at Thomas Jefferson University Hospital, Lankenau Medical Center and Children's Hospital of Philadelphia. Dr. Nelson previously served on staff at St. Christopher's Hospital for Children.
He earned a Doctor of Medicine degree from Harvard Medical School, as well as completed his surgical internship at New England Deaconess Hospital and ophthalmology residency at New York University, Bellevue Hospital Center. He went on to complete a fellowship in pediatric ophthalmology at the Children's National Hospital of GW University Hospital and fellowship in ocular genetics at the Wilmer Eye Institute of Johns Hopkins Medicine. Additionally, Dr. Nelson obtained his Master of Business Administration degree at St. Joseph's University and bachelor's degree in biology from Columbia University. He is the co-editor of the Journal of Pediatric Ophthalmology and Strabismus and authored over 300 publications and 15 textbooks in pediatric ophthalmology. He belongs to the American Association for Pediatric Ophthalmology and Strabismus and American Academy of Ophthalmology, among others.
"The NEXGEL team is constantly working to advance its mission of creating high-quality hydrogel products that can be worn by both consumers and patients for long periods of time with zero irritation," said Dr. Nelson. "I look forward to joining the Scientific Advisory Board to further NEXGEL's pursuit in developing these novel solutions for new indications."
In addition to Dr. Nelson, Dr. Chesen is a board-certified ophthalmologist who has been in private practice at Chesen Laser Eye Center for 33 years, with extensive experience in cataract and LASIK procedures. He is also board-certified in internal medicine – one of only 40 physicians in the U.S. with this double board certification. Dr. Chesen received his bachelor's degree in biology from Lafayette College and Doctor of Medicine degree from Jefferson Medical College. He completed his residency in internal medicine at Einstein Medical Center in Philadelphia and residency in ophthalmology at Nassau University Medical Center in East Meadow, N.Y. Dr. Chesen has hospital privileges at the Reading Hospital – Tower Health, Penn State Health St. Joseph Medical Center, where he is chairman of the department of ophthalmology, and Surgical Institute of Reading, where he currently serves as Board Chairman. He is a member of the American Academy of Ophthalmology.
"NEXGEL's high-water content hydrogel technology is extremely unique in that it is ultra-gentle on the skin and has numerous product applications across the entire healthcare landscape," added Dr. Chesen. "Through my decades of experience as an ophthalmologist, I see a lot of potential in these hydrogels for medicinal purposes, as well as the many others that NEXGEL currently has in its pipeline."
"As Drs. Chesen and Nelson are well-known leaders in the field of ophthalmology, NEXGEL will greatly benefit from their extensive medical knowledge and expertise as we continue to develop solutions using our hydrogels to help different kinds of patients around the U.S. and world," concluded Adam Levy, NEXGEL CEO.
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com
Media Contacts:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
212.896.1204 / 978.995.4683
rcona@kcsa.com / mfawcett@kcsa.com
LANGHORNE, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that the Company has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board.
宾夕法尼亚州朗霍恩,9月2022年29日(环球通讯社)--亚洲网加利福尼亚州圣何塞10月24日电用于医疗保健和消费应用的超温和、高水含量水凝胶产品的领先供应商奈克斯格尔公司(以下简称“奈克斯格尔”或“公司”)(纳斯达克市场代码:NXGL,NXGLW)今天宣布,公司已任命尼尔·切森博士和伦纳德·纳尔逊博士为科学顾问委员会成员。
Dr. Nelson serves as Co-Director of the pediatric ophthalmology department and Director of the Strabismus Center at Wills Eye Hospital. He is an associate professor of ophthalmology and pediatrics at Thomas Jefferson University's Sidney Kimmel Medical College and staff member at Thomas Jefferson University Hospital, Lankenau Medical Center and Children's Hospital of Philadelphia. Dr. Nelson previously served on staff at St. Christopher's Hospital for Children.
纳尔逊医生是威尔斯眼科儿科的董事联合研究员,也是威尔斯眼科斜视中心的董事的联合研究员。他是托马斯·杰斐逊大学西德尼·基梅尔医学院的眼科和儿科副教授,也是托马斯·杰斐逊大学医院、兰克瑙医学中心和费城儿童医院的工作人员。纳尔逊博士之前曾在圣克里斯托弗儿童医院任职。
He earned a Doctor of Medicine degree from Harvard Medical School, as well as completed his surgical internship at New England Deaconess Hospital and ophthalmology residency at New York University, Bellevue Hospital Center. He went on to complete a fellowship in pediatric ophthalmology at the Children's National Hospital of GW University Hospital and fellowship in ocular genetics at the Wilmer Eye Institute of Johns Hopkins Medicine. Additionally, Dr. Nelson obtained his Master of Business Administration degree at St. Joseph's University and bachelor's degree in biology from Columbia University. He is the co-editor of the Journal of Pediatric Ophthalmology and Strabismus and authored over 300 publications and 15 textbooks in pediatric ophthalmology. He belongs to the American Association for Pediatric Ophthalmology and Strabismus and American Academy of Ophthalmology, among others.
他获得了哈佛医学院的医学博士学位,并在新英格兰女执事医院完成了外科实习,并在纽约大学贝尔维尤医院中心完成了眼科住院医生的工作。随后,他在乔治华盛顿大学医院的国立儿童医院完成了儿科眼科的奖学金,并在约翰·霍普金斯医学院的威尔默眼科研究所完成了眼遗传学的奖学金。此外,纳尔逊博士在圣约瑟夫大学获得工商管理硕士学位,并在哥伦比亚大学获得生物学学士学位。他是The儿科眼科与斜视杂志撰写了300多种儿科眼科学出版物和15本教科书。他属于美国儿科眼科和斜视协会以及美国眼科学会等。
"The NEXGEL team is constantly working to advance its mission of creating high-quality hydrogel products that can be worn by both consumers and patients for long periods of time with zero irritation," said Dr. Nelson. "I look forward to joining the Scientific Advisory Board to further NEXGEL's pursuit in developing these novel solutions for new indications."
纳尔逊博士说:“NEXGEL团队一直在努力推进其使命,即创造高质量的水凝胶产品,消费者和患者都可以长时间佩戴,而不会产生刺激。”我期待着加入科学咨询委员会,进一步推动NEXGEL为新的适应症开发这些新的解决方案。“
In addition to Dr. Nelson, Dr. Chesen is a board-certified ophthalmologist who has been in private practice at Chesen Laser Eye Center for 33 years, with extensive experience in cataract and LASIK procedures. He is also board-certified in internal medicine – one of only 40 physicians in the U.S. with this double board certification. Dr. Chesen received his bachelor's degree in biology from Lafayette College and Doctor of Medicine degree from Jefferson Medical College. He completed his residency in internal medicine at Einstein Medical Center in Philadelphia and residency in ophthalmology at Nassau University Medical Center in East Meadow, N.Y. Dr. Chesen has hospital privileges at the Reading Hospital – Tower Health, Penn State Health St. Joseph Medical Center, where he is chairman of the department of ophthalmology, and Surgical Institute of Reading, where he currently serves as Board Chairman. He is a member of the American Academy of Ophthalmology.
除了纳尔逊博士,切森博士还是一名获得董事会认证的眼科医生,他在切森激光眼科中心私人执业已有33年,在白内障和LASIK手术方面拥有丰富的经验。他还获得了内科的董事会认证--这是美国仅有的40名拥有双重认证的医生之一。切森博士在拉斐特学院获得生物学学士学位,在杰斐逊医学院获得医学博士学位。他在费城的爱因斯坦医学中心完成了内科住院医师资格,并在纽约州东梅多市的拿骚大学医学中心完成了眼科住院医师资格。切森博士在雷丁医院-塔楼健康中心、宾夕法尼亚州立大学圣约瑟夫医疗中心(他在那里担任眼科主任)和雷丁外科研究所(他目前担任董事会主席)拥有医院特权。他是美国眼科学会的成员。
"NEXGEL's high-water content hydrogel technology is extremely unique in that it is ultra-gentle on the skin and has numerous product applications across the entire healthcare landscape," added Dr. Chesen. "Through my decades of experience as an ophthalmologist, I see a lot of potential in these hydrogels for medicinal purposes, as well as the many others that NEXGEL currently has in its pipeline."
切森博士补充说:“NEXGEL的高水分水凝胶技术非常独特,因为它对皮肤非常温和,在整个医疗保健领域有许多产品应用。”通过我几十年的眼科医生经验,我看到了这些用于医疗目的的水凝胶以及NEXGEL目前正在开发的许多其他水凝胶的巨大潜力。“
"As Drs. Chesen and Nelson are well-known leaders in the field of ophthalmology, NEXGEL will greatly benefit from their extensive medical knowledge and expertise as we continue to develop solutions using our hydrogels to help different kinds of patients around the U.S. and world," concluded Adam Levy, NEXGEL CEO.
NEXGEL首席执行官亚当·利维总结说:“由于切森博士和纳尔逊博士是眼科领域的知名领导者,随着我们继续利用我们的水凝胶开发解决方案,帮助美国和世界各地的不同类型的患者,NEXGEL将从他们丰富的医学知识和专业知识中受益匪浅。”
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
NEXGEL公司简介
NEXGEL是用于医疗保健和消费应用的超温和、高水含量水凝胶的领先供应商。该公司总部设在宾夕法尼亚州朗霍恩,开发和制造电子束、交联型水凝胶已有二十多年的历史。与其战略合作伙伴一起,NEXGEL已经配制了200多种不同的组合,将天然成分引入温和的皮肤贴片,可以长时间佩戴,几乎没有刺激性。
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com
投资者联系方式:
董事管理总监瓦尔特·平托
KCSA战略传播
212.896.1254
邮箱:valter@kcsa.com
Media Contacts:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
212.896.1204 / 978.995.4683
rcona@kcsa.com / mfawcett@kcsa.com
媒体联系人:
拉克尔·科纳/米凯拉·福塞特
KCSA战略传播
212.896.1204 / 978.995.4683
邮箱:rcona@kcsa.com/mfawcett@kcsa.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧